Watch AKTS. Know when insiders buy.
One email the day a filing lands. Free.
AKTS
Aktis Oncology, Inc.
19.63
−0.09 −0.46%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
71
PASS · shorts 71
Insiders, 90 days
−$259K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
FINANCIALS: NOT YET PULLED FROM SEC XBRL, CHECK BACK AFTER TONIGHT52W 15.19 – 32.23
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $3.4M | — | — | −$28.9M | −$24.1M | — | -0.44 | −$20.6M | $1.3M | −$21.8M | Aug 13 |
| Q1 2026 · Mar 31 | $3.2M | — | — | −$22.7M | −$18.3M | — | -0.38 | −$24.2M | $1.9M | −$26.1M | Aug 13 |
| Q2 2025 · Jun 30 | $1.6M | — | — | −$21M | −$18.1M | — | -22.39 | −$16.2M | $1.5M | −$17.7M | Aug 13 |
| Q1 2025 · Mar 31 | $1.4M | — | — | −$18.1M | −$15M | — | -18.60 | −$17.5M | $1.9M | −$19.4M | Aug 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|
Every number comes from Aktis Oncology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.